Skip to main content

The Role of Cell Metabolism in Development, Drug Resistance, and Survival Assessment in Cancer

39kviews
Editorial07 October 2025
Editorial: The role of cell metabolism in development, drug resistance, and survival assessment in cancer

Overview Cellular metabolism is a crucial increasingly established area in cancer research, significantly influencing disease progression and supporting tumor proliferation. Genetic alterations are usually crucial in cancer biology; however, it is now evident that tumor cells undergo significant metabolic reprogramming to promote proliferation, adapt to stress, and increase metastasis [1]. Disorders like Wilson's Disease underscore the significance of metabolic equilibrium. Tumorigenesis entails intricate alterations in the tricarboxylic acid (TCA) cycle, oxidative phosphorylation, amino acid metabolism, and lipid metabolism [2,3]. Nonetheless, the mechanisms by which these processes directly promote proliferation, metastasis, and resistance to therapy remain poorly elucidated. This Research Topic, "The Role of Cell Metabolism in Development, Drug Resistance, and Survival Assessment in Cancer," includes research and reviews that explore the metabolic pathways affecting carcinogenesis, progression, drug resistance, and prognosis. Critical studies addressed the function of metabolic pathways in treatment resistance and the prospects of metabolomics for biomarker identification. The publications together enhance the understanding of metabolism's influence on cancer and highlight novel treatment possibilities. Metabolic Reprogramming: Promoting Tumor Growth Cancer cells are metabolic opportunists, modulating glucose, lipid, and amino acid pathways beyond the traditional Warburg effect. This issue's articles illustrate how reprogramming drives carcinogenesis, metastasis, and chemoresistance. Niu et al. showed that fucoxanthin, a marine carotenoid, reduces the proliferation of acute myeloid leukemia by inhibiting AKT signaling and diminishing GLUT1-mediated glucose absorption (Front Pharmacol 2025). This demonstrates how the disruption of metabolic nodes reveals therapeutic vulnerabilities. Wang et al. investigated methylglyoxal (MG), a byproduct of glycolysis with dual functions in cancer. Depending on concentration and context, MG may either promote or inhibit tumor development, indicating its therapeutic potential in controlling MG (Front Oncol 2025). A number of studies have discovered prognostic metabolic markers. Wang et al. identified a reprogramming-based signature in small cell lung cancer (SCLC), connecting MOCS2 to chemotherapy sensitivity and immunological interactions (Front Mol Biosci 2025). Jiang et al. identified a metabolic profile based on MS4A7 as a predictive factor in lung cancer. Furuhashi et al. emphasized volatile organic compounds (VOCs) as non-invasive metabolic indicators, presenting potential for diagnosis and illness monitoring. Metabolic Mechanisms and Chemoresistance Drug resistance remains to be a significant obstacle to cancer, sometimes associated with metabolic adaptability [4]. The articles underscore the necessity of identifying metabolic vulnerabilities to overcome resistance. Niu et al. revealed that inhibiting AKT-mediated glucose metabolism may re-sensitize resistant cancers. Ma et al. assessed intra-tumor heterogeneity (ITH) in prostate adenocarcinoma (PRAD), demonstrating that metabolic variety promotes treatment resistance and emphasizing MYLK2 as a potential therapeutic target. Wang et al. examined MG's dual function in resistance, highlighting that its pro-tumorigenic effects are more significant in resistant cancers (Front Mol Biosci 2025). Taken together, these studies underscore that metabolic variability and plasticity contribute to therapeutic failure, and efforts to impede these adaptations are essential for sustained treatment efficacy. Clinical Metabolomics, Biomarkers, and Personalized Therapy Clinical metabolomics, which analyzes metabolites as immediate markers of tumor physiology, has significant promise for cancer diagnosis, prognosis, and therapeutic personalization. Wang et al. established that metabolic fingerprints may forecast the prognosis of small cell lung cancer (SCLC) and characterize immunological landscapes, suggesting that resistant and susceptible tumors show unique metabolic states. Jiang et al. confirmed that MS4A7-based gene expression patterns serve as prognostic markers in lung cancer. Both studies underscore the prognostic significance of metabolomics for patient outcomes. The research of Furuhashi et al. on volatile organic compounds (VOCs) illustrates a viable non-invasive biomarker platform. VOCs, identifiable in patient biofluids, may facilitate early diagnosis, progression tracking, and real-time evaluation of therapy. The study conducted by Ma et al. further substantiates the combination of metabolomic data with genetic profiles to formulate tailored therapies aimed at addressing specific metabolic vulnerabilities. These tactics seek to optimize efficacy and reduce toxicity. Conclusions and Prospective Direction The research included in this Research Topic emphasizes cellular metabolism as a fundamental catalyst of cancer formation, progression, and treatment resistance, rather than merely an outcome of malignancy. They collectively explain how metabolic reprogramming regulates tumor development, contributes to heterogeneity, and affects treatment results, while also emphasizing the potential of clinical metabolomics and non-invasive biomarkers for prognosis and customized therapy. In near future, the integration of metabolomic data with genetic and proteomic information will be essential for identifying new metabolic hubs, enhancing treatment approaches, and addressing resistance. Improving our comprehension of the interactions among metabolism, tumor biology, and the immune response brings us nearer to novel therapies that may improve survival and quality of life for patients.

2,303 views

1 citations

ORIGINAL RESEARCH
15 July 2025
Fucoxanthin inhibits the proliferation of MOLM13 cells by targeting AKT to disrupt glucose metabolism
Tingting Niu, 9 more and Qitian Mu

2,924 views

1 citations

Cancer treatment currently includes a variety of approaches. Chemotherapy, targeted therapy, and immunotherapy are combined based on cancer characteristics to develop personalized treatment plans. However, drug resistance can hinder the progress of treatment over time. Methylglyoxal (MG) is a metabolite with hormesis, exhibiting both pro-tumor and anti-tumor actions depending on its concentration during cancer progression. The MG-related metabolic pathway is being explored in the development of anti-cancer drugs, focusing on reducing MG stress or exploiting its cytotoxic effects to inhibit cancer progression. This article investigates the dual role of MG in cancer, emphasizing its effects on cell metabolism and tumor progression. It proposes MG capture therapy for the pre-cancerous stage and MG toxicity therapy for the cancer stage, contributing to the development of precise and individualized cancer treatments.

5,295 views

12 citations

ORIGINAL RESEARCH
28 April 2025
MS4A7 based metabolic gene signature as a prognostic predictor in lung adenocarcinoma
Yan Jiang, 7 more and Weicheng Zeng

5,120 views

4 citations

REVIEW
7 January 2025
Cancer is ranked as the top cause of premature mortality. Volatile organic compounds (VOCs) are produced from catalytic peroxidation by reactive oxygen species (ROS) and have become a highly attractive non-invasive cancer screening approach. For future clinical applications, however, the correlation between cancer hallmarks and cancer-specific VOCs requires further study. This review discusses and compares cellular metabolism, signal transduction as well as mitochondrial metabolite translocation in view of cancer evolution and the basic biology of VOCs production. Certain cancerous characteristics as well as the origin of the ROS removal system date back to procaryotes and early eukaryotes and share commonalities with non-cancerous proliferative cells. This calls for future studies on metabolic cross talks and regulation of the VOCs production pathway.
Review of cancer cell volatile organic compounds: their metabolism and evolution

5,539 views

24 citations